FDA to Regulate E-Cigarettes, Hookahs

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses new regulations from the FDA that subject e-cigarettes and hookahs to some of the same regulations as tobacco products.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses new regulations from the US Food and Drug Administration for e-cigarettes and hookahs.

For example, the new rules would require a valid photo ID for purchasing e-cigarettes and hundreds of e-cigarette products will now require regulatory review in order to stay on the market.

Recent Videos
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Related Content
ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

Ariana Pelosci
May 16th 2025
Article

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

Teclistamab is Feasible for Select Elderly Patients with Multiple Myeloma

Roman Fabbricatore
May 16th 2025
Article

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Mary Katherine L. Anderson, MD;James P. Fagerland, MD;Samantha Kohn, MD, MS;Amy C. Cannella, MD;Benjamin A. Teply, MD
May 16th 2025
Article

This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.

Expanding Horizons and Gaining Insights on T-DXd and Sacituzumab in Breast Cancer

Expanding Horizons and Gaining Insights on T-DXd and Sacituzumab in Breast Cancer

Ariana Pelosci
May 16th 2025
Article

Shannon L. Puhalla, MD, delves into the clinical application, efficacy, and safety profiles of T-DXd and sacituzumab govitecan for patients with breast cancer.